John Abraham: Telomere Biology Disorders – From Bench to Bedside
John Abraham, Assistant Professor at Christian Medical College and Hospital, shared a post on Linkedin about a recent article by Madeline Franke et al., published in Haematologica, adding:
“Telomere Biology Disorders (TBD): From Bench to Bedside
Recently revisited an excellent review in Haematologica (March 2026) by Madeline Franke et al., focusing on the diagnosis and management of adult telomere biology disorders.
Here are key takeaways
Core concept
TBD represent inherited defects in telomere maintenance leading to short telomeres, genomic instability, and multisystem disease.
Biology simplified
Telomeres (TTAGGG repeats) plus telomerase plus shelterin complex
- Maintain chromosomal integrity
- Progressive shortening triggers cell senescence and malignancy risk
Classification
- Short telomere syndromes (TBD) – organ failure, aging phenotype
- Long telomere syndromes (CPLT) – paradoxical increased cancer risk
Genetics
Mutations in key genes (TERT, TERC, DKC1, RTEL1, TINF2)
- Affect telomerase activity, trafficking, or telomere protection
Clinical spectrum (Adults)
- Bone marrow failure
- Interstitial lung disease (often the presenting feature)
- Liver fibrosis/portal hypertension
- Premature aging features
Cancer and hematology Risk
- MDS (approximately 500 fold increase risk)
- AML (20–70 fold increase risk)
- Clonal hematopoiesis plays a central role
Adaptive vs maladaptive clones (TP53, U2AF1)
Diagnosis
- Flow-FISH is clinical gold standard
- Genetic testing essential
- Up to 40% may lack identifiable mutations
Unique concepts
- Genetic anticipation – earlier, more severe disease
- Phenocopying – TBD phenotype without mutation
Management
- Androgens (e.g., danazol) – potential telomere elongation (mixed evidence)
- Transplant remains definitive (HSCT / lung / liver)
Requires reduced-intensity conditioning
Surveillance
- CBC plus marrow monitoring
- Cancer screening (H and N, skin, anogenital)
- Pulmonary and liver evaluation
Multidisciplinary care is key
Future directions
- Gene editing (ZSCAN4, TINF2)
- Telomerase-targeted therapies
Early-phase clinical trials underway
Take-home
Think TBD in:
- Unexplained cytopenias plus ILD plus family history
- Early greying plus marrow failure
- ‘Atypical’ MDS/AML in younger patients
Early recognition – better outcomes.”
Title: Diagnosis and management of adult telomere biology disorders
Authors: Madeline Franke, Alejandro Ferrer, Mrinal M. Patnaik
Read the Full Article on Haematologica
Stay updated with Hemostasis Today.
-
May 27, 2026, 17:51Nita Radhakrishnan: Post Graduate Institute of Child Health Receives WFH Data Quality Certification for Excellence
-
May 27, 2026, 17:51Fiona Robinson: What exactly Are Rebalancing Agents for Bleeding Aisorders?
-
May 27, 2026, 17:14Khurram Nasir: Can Earlier LDL-C Lowering Change the Trajectory of Cardiovascular Disease?
-
May 27, 2026, 17:09Yvonne Jongejan: Allele-Selective Silencing Therapy for VWD and Thrombotic Disorders
-
May 27, 2026, 16:58Catherine Moran: Important Step Forward as 1st WHO Resolution on Stroke Gets Adopted at WHA79
-
May 27, 2026, 16:08Heghine Khachatryan: Thrombosis in Oncology Remains a Major Healthcare Burden
-
May 27, 2026, 16:00Revealing Critical Gaps in Hemophilia Diagnosis and Access to Care in India – WFH
-
May 27, 2026, 16:00Melissa Hollo: Women Deserve Proactive Care, Not Reactive Care
-
May 27, 2026, 15:59Piotr Czempik: First Report of ROTEM Findings in Triple-Positive APS and Hageman Anomaly